Tandem Meetings 2023 | Single-agent lenalidomide maintenance after upfront autoSCT in newly diagnosed multiple myeloma

Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study exploring the safety and efficacy of single-agent lenalidomide maintenance after upfront autologous stem cell transplant (autoSCT) in patients with newly diagnosed multiple myeloma. While lenalidomide maintenance is now the standard of care (SOC) after autoSCT, the optimal maintenance duration and the efficacy of lenalidomide in patients with high-risk chromosomal abnormalities remain unclear. The study reported that lenalidomide maintenance improves progression-free survival (PFS), which is consistent with other findings. However, patients with high-risk characteristics did not get as much benefit from single-agent lenalidomide, suggesting other agents should be incorporated in maintenance strategies for these patients. Lastly, the study reported that 9% of patients developed a second primary malignancy (SPM). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.